Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Acceleron Pharma Inc (XLRN) USD0.001

Sell:$42.88 Buy:$42.91 Change: $0.36 (0.85%)
NASDAQ:0.72%
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
Sell:$42.88
Buy:$42.91
Change: $0.36 (0.85%)
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
Sell:$42.88
Buy:$42.91
Change: $0.36 (0.85%)
Market closed |  Prices as at close on 22 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Contact details

Address:
128 Sidney St
CAMBRIDGE
02139-4239
United States
Telephone:
+1 (617) 6499200
Website:
www.acceleronpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XLRN
ISIN:
US00434H1086
Market cap:
$2.25 billion
Shares in issue:
52.83 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Francois Nader
    Independent Chairman of the Board
  • Habib Dable
    President, Chief Executive Officer, Director
  • Kevin McLaughlin
    Chief Financial Officer, Senior Vice President, Treasurer
  • John Quisel
    Executive Vice President, Chief Business Officer, Secretary
  • Ravindra Kumar
    Senior Vice President, Chief Scientific Officer
  • Sujay Kango
    Senior Vice President and Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.